Amgen Inc. $AMGN Stock Holdings Lowered by Cullinan Associates Inc.

Cullinan Associates Inc. cut its position in Amgen Inc. (NASDAQ:AMGN) by 7.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 31,444 shares of the medical research company’s stock after selling 2,602 shares during the quarter. Cullinan Associates Inc.’s holdings in Amgen were worth $8,873,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Brighton Jones LLC raised its stake in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Gradient Investments LLC boosted its stake in Amgen by 0.6% during the 2nd quarter. Gradient Investments LLC now owns 47,236 shares of the medical research company’s stock valued at $13,189,000 after purchasing an additional 285 shares in the last quarter. Apella Capital LLC boosted its stake in Amgen by 33.0% during the second quarter. Apella Capital LLC now owns 1,773 shares of the medical research company’s stock valued at $519,000 after buying an additional 440 shares in the last quarter. NBC Securities Inc. lifted its holdings in Amgen by 11.4% in the 2nd quarter. NBC Securities Inc. now owns 7,435 shares of the medical research company’s stock valued at $2,075,000 after acquiring an additional 761 shares during the last quarter. Finally, Everpar Advisors LLC lifted its holdings in Amgen by 6.9% in the 2nd quarter. Everpar Advisors LLC now owns 2,360 shares of the medical research company’s stock valued at $659,000 after acquiring an additional 153 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Multiple sell‑side firms reiterated Buy ratings and bullish outlooks — William Blair kept a Buy, BMO highlighted pipeline momentum, and Goldman Sachs reiterated Buy with a $403 target, all reinforcing upside expectations for AMGN. Amgen: Durable Growth from Core Franchises and High‑Value MariTide Catalysts Support Buy Rating
• Positive Sentiment: Goldman Sachs cites strong portfolio execution and six growth drivers, keeping a high price target that suggests meaningful upside from current levels if execution continues. Amgen Growth Story Isn’t Tapped Out Yet, Says Goldman
• Positive Sentiment: Amgen reported extension and mid‑stage diabetes data for MariTide showing patients maintained weight loss and saw improved glycemic control — data that bolsters MariTide as a high‑value potential obesity/diabetes franchise. Amgen says MariTide helped trial patients maintain weight loss
• Neutral Sentiment: Amgen presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for longer‑term visibility on pipeline and strategy but not an immediate earnings surprise. Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Ro (telehealth) launched a research collaboration with Amgen to study barriers to obesity care and GLP‑1 access — this could help real‑world adoption and payer conversations over time but has no immediate revenue impact. Ro partners with Amgen to study barriers to obesity care, GLP-1 access
• Neutral Sentiment: Coverage pieces from Zacks highlight investor attention and potential earnings surprises in the sector — signals that AMGN is on screens but not a direct catalyst. These 2 Medical Stocks Could Beat Earnings
• Negative Sentiment: Despite the MariTide readouts, the stock fell as some investors said the data failed to excite — indicating a gap between expectations and what was disclosed, and suggesting near‑term volatility until larger confirmatory data or clearer commercial signals arrive. Amgen Stock (AMGN) Falls despite Obesity Drug Update — Here’s Wall Street’s Take

Amgen Price Performance

AMGN opened at $324.30 on Wednesday. The stock has a fifty day moving average of $330.88 and a 200-day moving average of $305.32. The firm has a market capitalization of $174.63 billion, a P/E ratio of 25.06, a PEG ratio of 2.97 and a beta of 0.45. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $346.38. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The business had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.Amgen’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio is 73.57%.

Insider Buying and Selling

In related news, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 10,908 shares of company stock worth $3,674,966. 0.69% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a report on Tuesday, November 11th. HSBC reiterated a “buy” rating and set a $425.00 price objective on shares of Amgen in a research report on Wednesday, December 10th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Wall Street Zen raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Monday, December 15th. Finally, Daiwa Capital Markets upped their target price on Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $338.55.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.